entertainment -WSS

entertainment

author：Wikipedia 2025-08-06 17:11:39 - browse：84

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — Two days after similar decisions in the U.S. and U.K., regulators in Europe on Friday recommended that the approval of Eli Lilly’s diabetes drug Mounjaro be widened to include obesity.

The ruling from a committee of the European Medicines Agency now goes to the European Commission, which makes the final decision but almost always follows the EMA’s guidance.

Mounjaro, known scientifically as tirzepatide, is one of an emerging class of drugs that target receptors of the GLP-1 hormone, and sometimes other molecules, and that have had dramatic effects on weight loss. Doctors have been prescribing the diabetes drugs off-label for obesity, but having specific authorization could streamline the process of getting the medicines.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Military medical care influenced by rank and race, new study finds

WSS

Wearables generate powerful data but its not useful to doctors, yet

Military medical care influenced by rank and race, new study finds

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

FDA scientists endorse Pfizer/BioNTech Covid

The a glaring gap in research on serious mental illness and primary care

entertainment

entertainment

hotspot

Bright Health sells Medicare Advantage business to Molina

Second House panel advances two

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Moonlake's readout produced a cash windfall. Risks remain

Cytokinetics CEO stresses company can launch heart drug on its own

Dobbs anniversary: the lost opportunity of abortion as health care

'Null' research findings aren't empty of meaning. Let's publish them

After affirmative action ruling, medical educators look to 'holistic review'

Second House panel advances two

leisure time

Group behind ProMed defends move to subscription

When prostate cancer spreads, where it goes matters

Data integrity in scientific journals requires "effort" by publishers, institutions

Solving academic medical centers' existential crisis

The cancer stories no one wants to hear

How to ethically and practically extend health care to all

hotspot

focus

Wikipedia

focus